Canada: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Health Canada Seeks Input On The Future Of NHP Quality Expectations
Health Canada has launched a public consultation on Version 4.0 of its Quality of Natural Health Products Guide, representing the first major revision since 2015. The draft guide has expanded from 46 to 132 pages, introducing substantially more detailed expectations for quality compliance under the Natural Health Products Regulations that will directly influence future inspection practices. This consultation offers manufacturers, packagers, labellers and importers a critical opportunity to shape regulatory
Canada Healthcare
GW
Gowling WLG
Article
Health Canada’s New Draft Guidance On Foreign Regulatory Reliance For Certain Drugs
Under the MRO, Health Canada may, in certain circumstances, rely on decisions or review documents produced by specified foreign regulatory authorities (“FRAs”) when reviewing eligible human and veterinary drug submissions. While Health Canada retains full authority for Canadian approval decisions, the framework introduces a mechanism through which portions of the review process can be deemed to have already been satisfied based on work performed by trusted international regulators.
Canada Healthcare
F
Fasken
See more

Food and Drugs Law

Article
The More Things Change, The More They Stay The Same: The Supreme Court Determines The Patentability Of Methods Of Medical Treatment
The Supreme Court of Canada has issued its most significant ruling on medical treatment patents in over fifty years, addressing whether dosing-regimen claims for schizophrenia medication constitute unpatentable methods of medical treatment. The 7-2 decision establishes a new framework for evaluating pharmaceutical patents, focusing on whether implementing the claimed invention requires professional medical skill and judgment. This landmark case provides crucial guidance for life sciences companies seeking p
Canada IP
C
Cassels
See more

Life Sciences, Biotechnology & Nanotechnology

Article
The Evolving Healthcare Deal Landscape
Healthcare M&A in Canada is experiencing a significant transformation, with total deal values surging from $4.5 billion to over $12 billion as pharmaceutical companies navigate patent cliffs and pursue revenue-generating assets. As artificial intelligence reshapes transaction assessments and intellectual property diligence becomes increasingly complex, dealmakers must adopt multidisciplinary approaches that integrate regulatory, data governance, and technology considerations into their strategic evaluations
Canada Commercial
TL
Torys LLP
See more

Healthcare

Article
The More Things Change, The More They Stay The Same: The Supreme Court Determines The Patentability Of Methods Of Medical Treatment
The Supreme Court of Canada has issued its most significant ruling on medical treatment patents in over fifty years, addressing whether dosing-regimen claims for schizophrenia medication constitute unpatentable methods of medical treatment. The 7-2 decision establishes a new framework for evaluating pharmaceutical patents, focusing on whether implementing the claimed invention requires professional medical skill and judgment. This landmark case provides crucial guidance for life sciences companies seeking p
Canada IP
C
Cassels
See more

Latest Videos

See more